An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 2 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-19.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.
Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2022, is one of 11 observational ones, and was the 5th registered.
62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.
Browse Moyamoya Disease studies →10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–70
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Beijing Tiantan Hospital · Sites in China
Ages 18–60 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–60
Beijing Tiantan Hospital · Sites in China
Healthy volunteers
By country, each count listing its studies:
Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: 2 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 400 is above the median of 300 across 29 observational studies indexed under Moyamoya Disease.
Median enrollment 328 across the 3 interventional studies, 350 across the 11 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
2 of the studies in Moyamoya Disease by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05332756Beijing Tiantan HospitalLong-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA) | 2026-11-30 |
| NCT07517354Beijing Tiantan HospitalFamily-Based Moyamoya Susceptibility and Early Detection | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. However, the long-term outcomes of MMD with conservative management remain unknown. Also, some first-degree relatives who are carriers of genetic variants occasionally manifest with intracranial arterial stenosis. Therefore, it is significant to detect the long-term outcomes of conservative treatment in MMD patients and their first-degree relatives, and thus provide potential pathogenesis of MMD.
Consecutive patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria. Relatives will be recruited from the first-degree relatives of patients with MMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Conservative management
Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Cerebrovascular events
Time frame: 6 months
Cerebrovascular events
Time frame: 1 year
Cerebrovascular events
Time frame: 2 years
Cerebrovascular events
Time frame: 5 years
Identification of RNF213 variants
Time frame: Baseline
Unfavorable neurological outcome (mRS>2)
Time frame: 6 months, 1 year, 2 years, and 5 years during follow-up
Change in cerebral perfusion status as assessed by CTP
Time frame: Baseline, 6 months, 1 year, 2 years, and 5 years during follow-up
Change in immunological, inflammatory, angiogenesis biomarkers of peripheral blood
Serum, plasma, RNA, immune cells and cytokines
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Change in angiographic features as assessed by CTA
Time frame: Baseline, 6 months, 1 year, 2 years, and 5 years during follow-up
Change in angiographic characteristics as assessed by MRA
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Change in radiological characteristics as assessed by HR-MRI
Time frame: Baseline, 1 year, 2 years, and 5 years during follow-up
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Nov 2026, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.